Ann: Achieve Clinics collaboration to expand reach of CHM CDH17, page-3

Achieve’s PRO-Aph transforms how patients access cell therapies because they do not have to
wait until the standard of care fails them before beginning to contemplate a possible future cell
therapy option. Waiting for cancer to progress while experiencing systemic chemotherapy
complicates the logistics of the leukopheresis and renders the collected cells less likely to deliver
an effective CAR T. PRO-Aph mitigates these issues by proactively collecting patients’ cells
while they are still at their healthiest point.
“The use of patients’ cells that have previously been exposed to chemotherapy and the logistical
challenges of just-in-time manufacturing have a negative impact both on patientstrying to access
these new medicines and cell therapy companies working to advance their clinical programs,”
said Jason B Litten MD, Chief Medical Officer of Chimeric. “We believe Achieve’s revolutionary
approach will streamline our future development plans and make it easier for patients to access
CHM CDH17.”

Finally some real step forwards when it comes to the COMPULSORY use of standard of care.

If CHM and Achieve can demonstrate a better outcome then this would be a real shift in treating cancer and the FDA would have to consider a change of current SoC rules.

We can verbally bash Hopper for failing on the $$$ front but on the medical front his Teams deliver and deliver.

GLTA